| Abstrakt: |
A study conducted by researchers at the National Cancer Institute (NCI) in Rio de Janeiro, Brazil, has found that patients with well-differentiated neuroendocrine neoplasms (NETs) who were treated with peptide receptor radionuclide therapy (PRRT) showed significant improvement in liver function and cholestasis parameters, as well as a decrease in bone marrow function. The study analyzed 110 patients who received 1 to 4 cycles of PRRT with Lu-177-DOTATATE between January 2011 and December 2021. The findings suggest that PRRT may be an effective treatment option for patients with liver metastasis from NETs. [Extracted from the article] |
